Selective ETA and dual ETA/ETB receptor antagonists are in clinical use for treatment of primary pulmonary arterial hypertension7 and ETA receptor blocker atrasentan has shown efficacy in reducing the risk of renal events in patients with diabetes and chronic kidney disease8. Here, EDNRA is linked to diabetes mellitus.